1046 related articles for article (PubMed ID: 16280765)
1. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
2. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
[TBL] [Abstract][Full Text] [Related]
3. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
6. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
7. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
8. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
10. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
11. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?
Divrik RT; Akdoğan B; Ozen H; Zorlu F
J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649
[TBL] [Abstract][Full Text] [Related]
13. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience.
Cresswell J; Scheitlin W; Gozen A; Lenz E; Teber D; Rassweiler J
BJU Int; 2008 Sep; 102(7):844-8. PubMed ID: 18537954
[TBL] [Abstract][Full Text] [Related]
15. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G
Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704
[TBL] [Abstract][Full Text] [Related]
16. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).
Ondrus D; Goncalves F; Kausitz J; Mat'oska J; Belan V
Neoplasma; 1996; 43(3):195-7. PubMed ID: 8841507
[TBL] [Abstract][Full Text] [Related]
17. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy analysis of three therapeutic modes on clinical stage Ia nonseminomatous germ cell testicular tumors].
Dong P; Liu ZW; Li XD; Wu S; Li YH; Yao K; Qin ZK; Han H; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2013 Mar; 51(3):256-60. PubMed ID: 23859330
[TBL] [Abstract][Full Text] [Related]
20. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
